AMRN: Bathi resik saben saham (EPS TTM) Amarin Corp

The loss of pricing power in the US due to generics, despite sustained demand for Vascepa, has caused operational strain and margin compression, as clearly demonstrated by the 12-month EPS history provided by the GURU.Markets platform, where the -0.91 mark records this metric. The stability of the cardiology defensive sector and the dependence on patent cycles complete the financial picture for Amarin Corporation plc (AMRN).
AMRN (Amarin Pharma): rincian analitis lan laporan miturut indikator

Amarin Corporation plc revenues depend on the commercialization of its patented fatty acid-based drug, making the monitoring of net earnings per share critical for assessing business efficiency. Analyzing the rolling earnings per share metric allows investors to strip away the impact of total shares outstanding and determine actual equity returns, preventing the purchase of an overvalued asset during a stagnation of fundamental indicators.